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Abstract Using contemporary stable-isotope methodology
and fluorescence microscopy, we assessed the impact of
carbohydrate supplementation on whole-body and fiber-
type-specific intramyocellular triacylglycerol (IMTG) and
glycogen use during prolonged endurance exercise. Ten
endurance-trained male subjects were studied twice during
3 h of cycling at 63±4% of maximal O2 uptake with either
glucose ingestion (CHO trial; 0.7 g CHO kg
−1 h
−1)o r
without (CON placebo trial; water only). Continuous
infusions with [U-
13C] palmitate and [6,6-
2H2] glucose
were applied to quantify plasma free fatty acids (FFA) and
glucose oxidation rates and to estimate intramyocellular
lipid and glycogen use. Before and after exercise, muscle
biopsy samples were taken to quantify fiber-type-specific
IMTG and glycogen content. Plasma glucose rate of
appearance (Ra) and carbohydrate oxidation rates were
substantially greater in the CHO vs CON trial. Carbohy-
drate supplementation resulted in a lower muscle glycogen
use during the first hour of exercise in the CHO vs CON
trial, resulting in a 38±19 and 57±22% decreased utiliza-
t i o ni nt y p eIa n dI Im u s c l e - f i b e rg l y c o g e nc o n t e n t ,
respectively. In the CHO trial, both plasma FFA Ra and
subsequent plasma FFA concentrations were lower, result-
ing in a 34±12% reduction in plasma FFA oxidation rates
during exercise (P<0.05). Carbohydrate intake did not
augment IMTG utilization, as fluorescence microscopy
revealed a 76±21 and 78±22% reduction in type I
muscle-fiber lipid content in the CHO and CON trial,
respectively. We conclude that carbohydrate supplementa-
tion during prolonged cycling exercise does not modulate
IMTG use but spares muscle glycogen use during the initial
stages of exercise in endurance-trained men.
Keywords Fatmetabolism.Intramyocellular
triacylglycerol.IMTG.Glycogen.Sportsdrinks.Isotopes.
Exercise
Introduction
During exercise, there is a complex interaction between
carbohydrate and fat metabolism to provide the required
adenosine triphosphate (ATP) to sustain the necessary
power output. The relative utilization of endogenous fat
and carbohydrate stores during exercise can vary enor-
mously and strongly depends on exercise intensity [28, 38],
duration [28, 41, 45], and training status [19, 36]. During
moderate intensity exercise, the oxidation of plasma-
derived free fatty acids (FFA) in conjunction with other
fat sources (muscle- and/or lipoprotein-derived triacylglyc-
erol) contributes approximately half of the total energy
required for contracting skeletal muscle. As the exercise
duration lengthens, there is an increasing contribution of fat
oxidation to total energy expenditure, which is primarily
attributed to an increase in the release, uptake, and
oxidation of plasma FFA [28, 41, 45]. Studies utilizing
more prolonged (≥2 h) moderate-intensity exercise proto-
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in plasma-FFA delivery to working skeletal muscle late in
the exercise coincides with an inhibition of intramyocellular
lipid (intramyocellular triacylglycerol [IMTG]) mobiliza-
tion and/or oxidation [28, 41, 45]. In accordance, pharma-
cological inhibition of adipose tissue lipolysis has been
shown to stimulate the use of intramyocellular lipids during
the latter stages of prolonged exercise [42, 44, 47].
Carbohydrate supplementation can also serve to decrease
FFA delivery and lower whole-body fat-oxidation rates
during exercise [9, 10]. Therefore, it could be hypothesized
that the reduced FFA availability via carbohydrate supple-
mentation stimulates IMTG use during the latter stages of
prolonged exercise. In contrast, other studies have reported
an inhibitory effect of glucose ingestion on hormone-
sensitive lipase activity [48], which would actually reduce
IMTG hydrolysis [11]. It therefore remains to be estab-
lished how carbohydrate supplementation during exercise
modulates IMTG utilization.
Carbohydrate supplementation during exercise has been
reported to improve endurance performance by maintaining
euglycemia during the late stages of prolonged exercise
and/or by sparing the muscle glycogen stores [9]. However,
the latter remains equivocal, as most studies have failed to
report muscle glycogen sparing after carbohydrate supple-
mentation during prolonged cycling exercise [5, 9, 13, 17,
24, 25]. The inconsistent findings of the effects of
carbohydrate supplementation on subsequent muscle gly-
cogen sparing may likely be attributed to differences in the
applied research design, with specific reference to the mode
of exercise (running vs cycling) and/or specific muscle
group and/or fiber type recruitment [33].
The present study applies continuous infusions of
[U-
13C] palmitate and [6,6-
2H2] glucose with muscle
biopsy sampling before and after exercise to quantify both
whole-body and muscle-fiber-type-specific IMTG and
glycogen use. The purpose of this study was to assess the
impact of carbohydrate supplementation on skeletal muscle
glycogen and intramyocellular lipid use during prolonged
cycling exercise in endurance-trained men and, as such, to
determine whether carbohydrate supplementation reduces
muscle glycogen use and/or augments the use of the IMTG
pool as a substrate source.
Materials and methods
Subjects
Ten endurance-trained male cyclists were selected to
participate in this study. Subjects’ characteristics are
provided in Table 1. Subjects were informed about the
nature and risks of the experimental procedures before their
written informed consent were obtained. This study was
approved by the local Medical Ethical Committee of the
Academic Hospital Maastricht.
Pretesting
Subjects initially performed a continuous incremental
cycling test on a cycle ergometer (LODE Instrument,
Groningen, The Netherlands) to exhaustion to determine
peak pulmonary oxygen uptake (VO2max; Oxycon-β,
Mijnhart, The Netherlands) and maximal workload capacity
(Wmax). After an overnight fast, body composition was
assessed using the hydrostatic weighing method, with
corrections made for residual lung volume via the helium
dilution technique (Volugraph 2000, Mijnhart, Bunnik,
Netherlands). Body-fat percentage was calculated using
Siri’s[ 31] equation. To assess whole-body insulin sensitiv-
ity an oral glucose tolerance test was performed in each
subject according to the World Health Organization criteria
[2]. In addition, insulin resistance was estimated using the
homeostasis model assessment for insulin resistance or
HOMA-IR index [23].
Diet and activity before testing
All subjects were instructed to maintain their usual dietary
and physical activity patterns throughout the entire exper-
imental period. In addition, they filled out a food intake
diary for 2 days before the first exercise trial to keep their
dietary intake as identical as possible before the other trials.
Subjects refrained from heavy physical labor and exercise
training for 3 days before each trial. Dietary analyses
showed no differences in energy intake during the days
before each of the trials with an average energy intake of
Table 1 Subjects’ characteristics (n=10)
Characteristics
Age (years) 23±3
Height (m) 1.83±0.04
Body mass (kg) 72.5±9.6
BMI (kg m
−2) 21.7±1.9
Body fat percentage (%) 9.8±2.4
Fat free mass (kg) 65.3±7.9
Basal plasma glucose (mmol l
−1) 5.1±0.3
Plasma glucose120 min (mmol l
−1) 3.9±1.1
Basal plasma insulin (mU l
−1) 9.0±2.6
HbA1c (%) 5.2±0.2
VO2max (ml kg
−1 min
−1) 59.8±5.6
Wmax (W) 398±41
Values are expressed as means ± SD. Body mass index (BMI)i s
calculated by dividing body mass by the square of the height.
Plasma glucose120 min Plasma glucose concentration 120 min after
ingesting 75 glucose in the oral glucose tolerance test
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intake (energy%) derived from carbohydrate, fat, and
protein, respectively. The evening before each trial, subjects
received the same standardized meal (41.2 kJ kg bw
−1;
containing 72, 11, and 17 energy% carbohydrate, fat, and
protein, respectively).
Experimental trials
Each subject performed three trials, separated by at least
1 week: two experimental trials (CON: control vs CHO:
carbohydrate) and an acetate correction trial (Fig. 1). Each
trial consisted of 60 min of resting measurements, followed
by 180 min of cycling at 50%Wmax. In the main trials, an
[U-
13C] palmitate and [6,6-
2H2] glucose tracer were infused
continuously at rest and during exercise with breath and
blood samples collected at regular intervals. Muscle biopsy
samples were collected before and immediately after
exercise. In the carbohydrate supplementation trial (CHO),
plasma FFA availability was reduced, and plasma glucose
availability was augmented through carbohydrate ingestion.
To allow for a continuous supply of glucose from the gut,
subjects ingested an 8% CHO solution every 20 min during
exercise at the rate of 0.7 g CHO kg
−1 h
−1, as recommended
by the American College of Sports Medicine [1]. In the
control trial, a placebo water drink was provided (CON). In
a third trial, [1,2-
13C] acetate was infused continuously at
rest and during exercise, and only breath samples were
collected. Both the CON and acetate trials were performed
in an overnight fasted state. The acetate recovery factor was
used to accurately correct [U-
13C] palmitate oxidation rates
for carbon label retention in the bicarbonate pool(s) and by
way of isotopic exchange reactions in the TCA-cycle for
each subject [40].
Protocol
After an overnight fast, subjects arrived at the laboratory at
8:00 A.M. by car or public transportation. After 30 min of
supine rest, a percutaneous muscle biopsy was taken from
the vastus lateralis muscle [3]. A Teflon catheter (Baxter,
Utrecht, The Netherlands) was inserted into an antecubital
vein of one arm for blood sampling, another catheter was
inserted in the antecubital vein of the contralateral arm for
isotope infusion. Thereafter, a resting blood sample was
taken and expired breath samples were collected into
vacutainer tubes. Subsequently, subjects were administered
a single intravenous dose of NaH
13CO3 (0.06375 mg kg
−1),
to prime the bicarbonate pool(s), followed by a [6,6-
2H2]
glucose prime (13.5 μmol kg
−1). Thereafter, a continuous
infusion of [6,6-
2H2] glucose (0.3 μmol kg
−1 min
−1) and
[U-
13C] palmitate (0.01 μmol kg
−1 min
−1; or [1,2-
13C]
acetate in the acetate recovery trial) was started (t=0 min)
via a calibrated IVAC pump (IVAC 560, San Diego, CA)
and continued for 4 h. At t=60 min, an initial drink bolus
(7 ml kg
−1) was given, and then nine more drink boluses
(2.5 ml kg
−1) were given at t=80, 100, 120, 140, 160, 180,
200, 220, and 240 min of either an 8% carbohydrate
solution or a placebo. At t=60 min, subjects started to
exercise on a cycle ergometer at a workload of 50%Wmax for
3 h. Expired VO2 and VCO2 were measured (Oxycon-β)
at rest and throughout exercise for 5 min every 20 min
before sampling of blood and expired breath collection.
Immediately after cessation of exercise, a second muscle
Fig. 1 Schematic of study pro-
tocol. After an initial resting
blood, breath, and muscle biop-
sy sample, a continuous infusion
with [U-
13C] palmitate and
6,6-
2H2 glucose was started for
240 min. At rest and during 3 h
of cycling at 50% of Wmax
substrate use was assessed with
(CHO trial) and without
(CON trial) carbohydrate
supplementation
Pflugers Arch - Eur J Physiol (2007) 454:635–647 637biopsy was taken (t=240 min). Breath and blood samples
were collected at t=0, 30, and 60 min (during rest) and at
t=80, 100, 120, 140, 160, 180, 200, 220, and 240 min
(during exercise).
Beverages
In the CHO trial, subjects received a beverage volume of
2.5 ml kg
−1 every 20 min to ensure a given dose of 0.7 g
CHO kg
−1 (50% as glucose and 50% as maltodextrin) every
hour. Repeated boluses were administered to enable a
continuous supply of glucose in the circulation, preventing
perturbations in [6,6-
2H2] glucose enrichment. In the CON
trial, a sweetened placebo drink, which contained no
carbohydrate, was provided. Glucose and maltodextrin
were obtained from AVEBE (Veendam, The Netherlands).
To make the taste comparable in all experiments, beverages
were uniformly flavored by adding 0.2 g sodium–saccharine
solution (25% w/w), 1.8 g citric acid solution (50% w/w),
a n d5go fc r e a mv a n illa flavor (Numico Research,
Wageningen, The Netherlands) for each liter of beverage.
Experiments were performed in a randomized order, with
test drinks provided in a double-blind fashion.
Tracer infusion
Infusion rates of [U-
13C] palmitate and [6,6-
2H2] glucose
averaged 7.3±0.8 and 817.5±30.4 nmol kg
−1 min
−1,
respectively, in the CON and CHO trial. At the onset of
exercise, [U-
13C] palmitate infusion rates were doubled
(14.6±1.6 nmol kg
−1 min
−1). In the acetate recovery trial, a
corresponding amount of
13C was infused, resulting in an
average [1,2-
13C] acetate infusion rate of 61.6±2.4 and
123±5 nmol kg
−1 min
−1 at rest and during exercise,
respectively. Palmitate, glucose, and acetate tracer concen-
trations in the infusates averaged 1.03±0.07, 64.8±7.2, and
4.74±0.18 mmol l
−1, respectively.
Blood- and breath-sample analysis
Blood samples (7 ml) were collected in ethylenediamine
tetraacetic acid (EDTA)-containing tubes and centrifuged at
1,000×g for 10 min at 4°C. Aliquots of plasma were frozen
immediately in liquid nitrogen and stored at −80°C. Plasma
glucose (Uni Kit III, Roche, Basel, Switzerland), lactate
[16], FFA (NEFA-C, Wako Chemicals, Neuss, Germany),
free glycerol (148270, Roche Diagnostics, Indianapolis,
IN), and triglyceride (TG; GPO-trinder 337B, Sigma
Diagnostics, St. Louis, MO) concentrations were analyzed
with a COBAS semi-automatic analyzer (Roche).
Expired breath samples were analyzed for
13C/
12C ratio
by gas chromatography continuous flow isotope ratio mass
spectrometry (GC-IRMS; Finnigan MAT 252, Bremen,
Germany). For determination of plasma palmitate and
FFA kinetics, FFA were extracted from plasma, isolated
by thin-layer chromatography, and derivatized to their
methyl esters. Palmitate concentration was determined on
an analytical gas chromatograph with flame ionization
detection using heptadecanoic acid as an internal standard
and on average comprised 26±2 and 24±3% of total FFA
for the CON and CHO trials, respectively. Isotope tracer/
tracee ratio of [U-
13C] palmitate was determined using GC-
combustion IRMS (Finnigan MAT 252). Plasma glucose
was first extracted with chloroform–methanol–water and
derivatization was performed with butylboronic acid and
acetic anhydride as described previously [27]. After
derivatization, plasma [6,6-
2H2] glucose enrichment was
determined by electron ionization GC-MS (Finnigan
INCOS-XL). Glucose (Uni Kit III, Roche) and acetate
(Kit 148261, Boehringer) concentrations in the infusates
were determined with the COBAS FARA.
Calculations
From respiratory measurements, total fat and carbohydrate
oxidation rates were calculated using the nonprotein
respiratory quotient [26].
Fatoxidationrate ¼ 1:695 VO2   1:701 VCO2 ð1Þ
Carbohydrate oxidation rate ¼ 4:585VCO2   3:22VO2
ð2Þ
with VO2 and VCO2 in liters per minute (l min
−1) and
oxidation rates in grams per minute (g min
−1). Breath and
plasma enrichments are expressed as tracer/tracee ratios
(TTR);
TTR ¼ 13C
12C

sa   13C
12C

bk ð3Þ
in which sa indicates sample and bk indicates background
value. Rate of palmitate and glucose appearance (Ra) and
disappearance (Rd) were calculated using the single-pool
nonsteady-state Steele [32] equations adapted for stable
isotope methodology as described elsewhere [49]. As such,
plasma palmitate and glucose Rd were calculated by
correcting the Ra for the time-dependent changes in plasma
metabolite concentration.
Ra ¼
F   VC 2 þ C1 ðÞ =2 ½  E2   E1 ðÞ = t2   t1 ðÞ ½ 
E2 þ E1 ðÞ =2
ð4Þ
Rd ¼ Ra   V
C2   C1
t2   t1

ð5Þ
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−1 min
−1); V is the
distribution volume for palmitate or glucose (40 and 160 ml
kg
−1, respectively); C1 and C2 are the palmitate or glucose
concentrations (mmol l
−1) at time 1(t1) and 2(t2), respec-
tively, and E2 and E1 are the plasma palmitate or glucose
enrichments (TTR) at time 1 and 2, respectively.
13CO2
production (Pr
13CO2; mol min
−1) from the infused palmi-
tate tracer was calculated as:
Pr13CO2 ¼ TTRCO2VCO2 ðÞ = kAr ðÞ ð 6Þ
where TTRCO2 is the breath
13C/
12C ratio at a given time
point, VCO2 is the carbon dioxide production (l min
−1), k is
the volume of 1 mol of CO2 (22.4 l mol
−1), and Ar is the
fractional
13C label recovery in breath CO2 observed after
the infusion of labeled acetate [30] and calculated as:
Ar ¼ TTRCO2VCO2=k2F ðÞ ð 7Þ
where F is the infusion rate of [1,2-
13C] acetate (mol
min
−1). Plasma palmitate oxidation (Rox; mol min
−1) can
subsequently be calculated as:
Rox palmitate ¼ Rd palmitate Pr13CO2

F16

ð8Þ
where Rd palmitate is the rate of palmitate disappearance
(mol min
−1); F is the palmitate infusion rate (mol min
−1),
and 16 is the number of carbon atoms in palmitate. Total
plasma FFA oxidation was calculated by dividing palmitate
oxidation rates by the fractional contribution of plasma
palmitate to total plasma FFA concentration. Muscle
derived TG use was estimated by subtracting plasma FFA
oxidation from total fat oxidation. However, it should be
noted that the indirect stable isotope methodology does not
differentiate between muscle- and lipoprotein-derived TG
use. However, the contribution of lipoprotein-derived TG
oxidation to total energy expenditure is assumed to be of
relative minor quantitative importance, especially in an
overnight-fasted state [37].
In a previous study, where we applied both an [U-
13C]
and [6,6-
2H2] glucose tracer [18] during moderate intensity
exercise, it was shown that the percentage of plasma
glucose Rd that was oxidized varied between 96–100%.
Therefore, plasma glucose oxidation rate during exercise
was calculated as:
Rox plasmaglucose¼ Rd plasmaglucose duringexercise ðÞ
ð9Þ
Therefore, muscle glycogen oxidation was calculated by
subtracting plasma glucose oxidation from total carbohy-
drate oxidation.
Muscle-sample analyses
Muscle tissue samples were freed from any visible nonmuscle
material and rapidly frozen in liquid nitrogen. About 15 mg of
each muscle sample was frozen in liquid nitrogen-cooled
isopentane and embedded in Tissue-Tek (Sakura Finetek,
Zoeterwoude, The Netherlands). Multiple serial sections
(5 μm) from all biopsy samples were thaw mounted together
per subject on uncoated, precleaned glass slides and stained
with either acid-Schiff (PAS) [29] or immunolabelled oil red
O[ 21] to measure fiber-type-specific glycogen or intra-
myocellular lipid content, respectively. To determine the
muscle-fiber typing, (type I vs type II), we performed a
myosin adenosine 5′-triphosphatase stain [22]. As previously
described, the applied fluorescence and bright field micros-
copy techniques represent semiquantitative methods that can
be used to compare fiber-type-specific IMTG and glycogen
content [39, 41, 43, 44]. Fiber-type-specific IMTG content
was expressed as the fraction of the measured area that was
stained with oil red O. For IMTG quantification, average
lipid-droplet size was calculated by dividing the total number
of lipid aggregates by the total area measured. Mixed muscle-
lipid content, lipid-droplet size, and lipid-droplet density were
determined by calculating the average value in the type I and
type II muscle fibers, with a correction for the relative area
occupied by each fiber type within each field of view of each
muscle cross-section, within each individual subject. The oil
red O epifluorescence signal was recorded for each muscle
fiber resulting, on average, in a total of 71±19 muscle fibers
analyzed for each muscle cross-section (45±14 type I, 26±10
type II) per subject. The PAS bright-field images were
converted post hoc into eight-bit grayscale values to quantify
glycogen. The mean optical density of the PAS-stained
muscle fibers were determined by averaging the optical
density measured in every pixel in the cell, corrected for the
mean optical density of the background stain, containing no
muscle fibers. For PAS analysis, on average per subject, a
total of 151±61 muscle fibers were analyzed for each muscle
cross-section (92±32 type I, 59±26 type II).
Statistics
All data are expressed as mean ± SD. Before statistical
analysis, data normality was confirmed at P>0.05 using the
Kolmogorov–Smirnov test on log-transformed raw data. To
compare tracer kinetics, substrate utilization rates, IMTG
contents, and/or plasma metabolite concentrations over time
between trials, a two-way repeated measures analysis of
variance was applied. When a significant F ratio was
obtained, post hoc analyses were completed using a
Student–Newman–Keuls test. For nontime-dependent vari-
ables, a Student’s t test for paired observations was used.
Statistical significance was accepted at P<0.05.
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Plasma metabolite and hormone concentrations
Plasma FFA, triacylglycerol (TG), glycerol, glucose, lac-
tate, and insulin concentrations over time during exercise
are shown in Fig. 2. There were no differences in plasma
FFA and glycerol between trials at rest or during the first
40 min of exercise (Fig. 2a,c). However, at all time points
after 60 min, plasma FFA and glycerol concentrations
increased over time in both trials, but levels remained
significantly lower in the CHO vs CON trial (P<0.01).
Plasma TG levels declined throughout exercise in both
trials but were significantly higher in the CHO vs the CON
trial (P<0.05; Fig. 2b). Plasma glucose concentrations
increased in the CHO trial at the initiation of carbohydrate
Fig. 2 Plasma metabolite concentrations during 3 h of cycling at 50% Wmax in CON and CHO trials. Values are means ± SD, n=10. Crosses,
significantly different than CON trial (P<0.05)
640 Pflugers Arch - Eur J Physiol (2007) 454:635–647ingestion and were significantly higher in the CHO vs CON
trial (P<0.05; Fig. 2d). Over the last hour of exercise,
plasma glucose steadily declined in both trials but remained
significantly higher in the CHO vs CON trial. Plasma
insulin levels in the CHO trial significantly increased
during the initial 90 min of exercise as compared to CON
(P<0.05; Fig. 2f). Thereafter, plasma insulin steadily
declined in both trials. Plasma lactate concentrations
increased above baseline levels, with plasma lactate con-
centrations being greater in the CHO vs CON trial (Fig. 2e).
In contrast, during the latter stages of exercise, significantly
higher plasma lactate levels were observed in the CON vs
CHO trial. Plasma norepinephrine concentrations increased
threefold within the first 20 min of exercise and continued
to rise throughout the exercise period in both trials, with no
significant differences between trials (Fig. 3). Plasma
epinephrine levels increased gradually in both trials during
the first 2 h of exercise, after which, levels increased
substantially (P<0.001; Fig. 3). However, in the CHO trial,
there was an attenuated increase in epinephrine, resulting in
significantly (P<0.05) lower concentrations vs CON.
Plasma tracer kinetics
As plasma FFA and glucose concentrations varied over
time in both trials (Fig. 2a,d), nonsteady-state Steele [32]
equations were applied to calculate tracer kinetics. At rest,
tracer kinetics did not differ between trials as carbohydrate
supplementation did not start until the onset of exercise.
At rest, plasma glucose Ra and Rd averaged 14.9±1.6 and
15.0±1.8 μmol kg
−1 min
−1, respectively. Resting palmitate
Ra, Rd, and Rox averaged 1.92±0.43, 1.89±0.55, and 0.74±
0.22 μmol kg
−1 min
−1, respectively, with 38±4% of
palmitate Ra being oxidized. The onset of exercise
significantly elevated plasma glucose and palmitate Ra,
Rd, and/or Rox (Table 2). Plasma glucose Ra and Rd, and
palmitate Ra, Rd, and Rox increased continuously during the
exercise in both trials (Table 2). During the entire exercise
period, average glucose Ra and Rd was 49±9% greater in
the CHO compared with the CON trial (P<0.05; Table 2).
In contrast, plasma palmitate Ra, Rd,a n dRox was 41±12%
lower during exercise in the CHO vs CON trial (P<0.05;
Fig. 3 Plasma catecholamine concentrations during 3 h of cycling at
50% Wmax in CON and CHO trials. Values are means ± SD, n=10.
Crosses, significantly different from the CON trial (P<0.05)
Table 2 Tracer kinetics and respiratory measures during exercise
First hour Second hour Third hour Exercise average
CON CHO CON CHO CON CHO CON CHO
Glucose
Ra (μmol kg
−1 min
−1) 21.1±2.7 46.8±9.6
a 28.8±4.8 55.8±6.8
a 38.1±7.5 72.9±8.2
a 30.4±4.7 59.9±7.2
a
Rd (μmol kg
−1 min
−1) 21.9±3.1 48.3±12.3
a 30.3±7.9 60.0±11.2
a 39.5±7.2 72.9±8.5
a 31.7±4.7 61.9±7.3
a
Palmitate
Ra (μmol kg
−1 min
−1) 2.49±0.80 2.03±0.40
a 3.55±0.78 1.97±0.57
a 6.43±0.89 3.60±1.92
a 4.36±0.71 2.59±0.70
a
Rd (μmol kg
−1 min
−1) 2.48±0.79 2.06±0.40
a 3.50±0.79 1.96±0.56
a 6.36±0.88 3.57±1.34
a 4.32±0.70 2.58±0.69
a
Rox (μmol kg
−1 min
−1) 2.28±0.73 1.84±0.42
a 3.49±0.72 1.91±0.68
a 6.35±0.73 3.62±1.38
a 4.26±0.59 2.53±0.77
a
%Ra ox 91.5±5.9 90.9±8.6 98.7±5.83 95.6±8.8 99.4±7.8 99.8±7.0 97.2±6.2 96.0±6.8
Ac recovery 81.7±5.7 – 86.5±4.7 – 86.2±4.1 – 85.8±3.9 –
Respiratory measures
VO2 (ml) 2,666±91 2,690±90 2,713±88 2,709±98 2,773±93 2,772±109 2,717±89 2,724±97
VCO2 (ml) 2,361±81 2,412±76 2,336±76 2,424±84
a 2,327±88 2,453±94
a 2,342±79 2,430±83
a
RER 0.89±0.01 0.90±0.01 0.86±0.01 0.90±0.01
a 0.84±0.01 0.89±0.01
a 0.86±0.01 0.89±0.01
a
Values are expressed as means ± SD, n=10. Tracer kinetics during each hour of exercise and averaged during 3 h of cycling at 50% Wmax in the
CON and CHO trial.
Ra Rate of appearance; Rd rate of disappearance; Rox rate of oxidation; %Ra ox %Ra palmitate oxidized; Ac recovery fraction 1,2-
13C acetate label
recovery in expired CO2
aSignificantly different compared with the CON trial (P<0.05)
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value during exercise and averaged 86±4% of the acetate
infusion rate. In a pilot experiment, we confirmed that
carbohydrate supplementation does not affect acetate label
recovery during exercise, which was in accordance to
previous findings [44].
Substrate source utilization at rest
There were no differences in total resting energy expenditure
(5.37±0.52 vs 5.32±0.53 kJ min
−1 in the CON and CHO trial,
respectively) or substrate source utilization rates between trials.
Total fat oxidation averaged 0.08±0.01 g min
−1, contributing
58±6% to total energy expenditure. Plasma FFA oxidation
rates averaged 0.061±0.011 g min
−1, contributing 53±7 to
total energy expenditure at rest. The use of muscle- and/or
lipoprotein-derived TG sources averaged 0.016±0.008 g
min
−1 and contributed 7±20% to total energy expenditure.
Total carbohydrate oxidation rates averaged 0.13±0.03 g
min
−1, contributing 42±6% to total energy expenditure.
Substrate source utilization during exercise
The applied 50% Wmax workload resulted in subjects
c y c l i n ga t1 9 9 ± 2 1W ,c o r r e sponding with a relative
workload intensity of 63±1% VO2max From rest to
exercise, energy expenditure increased tenfold. No differ-
ences in energy expenditure were observed over time or
between trials (57.3±5.9 and 57.8±6.4 kJ min
−1 in the
CON and CHO trial, respectively; Fig. 5). Total carbohy-
drate oxidation rates were significantly higher in the CHO
vs the CON trial (2.35±0.37 vs 1.97±0.33 g min
−1,
respectively; P<0.001). Concomitantly, total fat oxidation
rates were higher in the CON vs CHO trial (0.62±0.12 vs
0.48±0.16 g min
−1, respectively; P<0.001). In the CHO
trial, carbohydrate and fat oxidation contributed 66±6 and
34±5% to total energy, respectively. In the CON trial,
carbohydrate and fat oxidation contributed 56±5 and 44±
7% to total energy expenditure during exercise.
The use of specific substrate sources over time during
exercise is illustrated in Fig. 4. The calculations for
substrate source utilization in Figs. 4 and 5 commences at
40 min because of the nonsteady-state transition from rest
to exercise. Plasma FFA and glucose oxidation rates
increased over time in both trials (P<0.01; Fig. 4a,c). In
contrast, the respective use of muscle- (and lipoprotein)
derived TG and glycogen declined over time (P<0.01;
Fig. 4b,d). Plasma glucose oxidation was significantly
greater in the CHO vs CON trial and averaged 13.2±2.1 vs
6.7±1.1 kJ min
−1,r e s p e c t i v e l y( P<0.001: Fig. 4c). Plasma
FFA oxidation rates were substantially greater in the CON vs
CHO trial and averaged 13.8±2.9 vs 9.1±2.8 kJ min
−1,
respectively (P<0.001; Fig. 4a). No significant differences
were observed in the use of muscle (and lipoprotein-derived)
TG and glycogen over time between trials.
Figure 5 illustrates average substrate source utilization
rates calculated over each consecutive hour of exercise.
During the first hour of exercise, there were no differences
in endogenous fat source utilization between trials. In
contrast, plasma glucose oxidation rates were higher in the
CHO trial, resulting in a 10±6% lower glycogen use
compared with the CON trial (P<0.05; Fig. 5). During the
latter stages of exercise, plasma glucose oxidation rates
remained higher in the CHO vs CON trial, with no
differences in muscle glycogen use between trials (Fig. 5).
In the first hour, fat contributed nearly the same amount of
energy in the CON and CHO trial, 36±6 and 33±7%,
respectively. In contrast, during the second and third hour
of exercise, total fat oxidation rates increased substantially,
with greater fat use in the CON vs CHO trial. By the third
hour, fat oxidation contributed 51±8% to total energy
expenditure in the CON trial, whereas fat oxidation
contributed only 36±9% in the CHO trial (P<0.01; Fig. 5).
In the CHO trial, the attenuated increase in fat oxidation
rate during exercise was offset by a significant increase in
total carbohydrate oxidation rate. Total carbohydrate oxi-
dation rates during exercise averaged 1.97±0.33 and 2.35±
0.37 g min
−1 in the CON and CHO trial, respectively
(P<0.01). As there were no differences in the average rate of
glycogen utilization between treatments during the second
and third hour of exercise (Figs. 4da n d5), the increased
carbohydrate use in the CHO trial was fully attributed to
increases in plasma glucose oxidation over the last 2 h of
cycling (Figs. 4ca n d5). Muscle (and lipoprotein-derived)
TG and glycogen use declined over time but did not differ
between trials during the latter stages of exercise (Fig. 5).
Skeletal muscle lipid content
Preexercise fiber-type-specific muscle IMTG was not
different between conditions and averaged 0.067±0.025
and 0.018±0.010 arbitrary units (AU) in type I and II
muscle fibers, respectively. There was a significantly
greater net decline in intramyocellular lipid content in the
type I vs type II muscle fibers after exercise (Fig. 6a). No
differences in the net decline in myocellular lipid content
were observed between trials. Exercise resulted in a 76±21
and 78±22% reduction in type I muscle-fiber lipid content
in the CHO and CON trial, respectively (P<0.01). Type II
muscle-fiber lipid content was not significantly reduced
after exercise and showed a net decline of 0.003±0.014 and
0.008±0.0012 AU in the CHO and CON trials, respectively
(P=NS). The observed decrease in type I muscle intra-
myocellular lipid content was attributed to significant
decreases in both lipid-droplet size (preexercise, 0.560±
0.150; vs postexercise, 0.359±0.152 μm
2) and lipid-droplet
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source utilization (kJ min
−1)
during the first, second, and
third hour of cycling and aver-
aged over the entire 3 h, at 50%
Wmax in the CON and CHO trial.
Crosses, plasma FFA, other fat
sources, total carbohydrate, and/
or plasma glucose and/or glyco-
gen use significantly different
from the CON trial (P<0.05)
Fig. 4 a Plasma FFA, b other fat sources, c plasma glucose, and d muscle glycogen rate of oxidation (kJ min
−1) during 3 h of cycling at 50%
Wmax in CON and CHO trials. Values are means ± SD, n=10. Crosses, significantly different from CON trial (P<0.05)
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0.022 droplets μm
−2).
Skeletal muscle glycogen content
At rest, glycogen contents did not differ between trials
(0.087±0.018 vs 0.103±0.021 AU in the CHO vs CON
trial, respectively; P>0.05) or between fiber types (0.095±
0.019 vs 0.094±0.021 AU in the type I vs type II muscle
fibers, respectively; P>0.05). Exercise resulted in a
significantly greater net reduction in muscle glycogen
content in the type I vs the type II muscle fibers (P<0.05;
Fig. 6b). The net decline in muscle glycogen content after
exercise was significantly greater in the CON vs the CHO
trial (38±19 and 57±22% greater in the type I and II
muscle fibers, respectively; P<0.01)
Discussion
The aim of this study was to examine substrate source
utilization with (CHO) or without (CON) carbohydrate
supplementation on subsequent glycogen and IMTG use
during prolonged cycling exercise in endurance-trained
male cyclists. Carbohydrate ingestion increased total
carbohydrate oxidation, which was entirely attributed to a
greater plasma glucose appearance (Ra) and disappearance
(Rd) rate. The greater glucose availability in the CHO trial
lowered muscle glycogen use during the first hour of
exercise, resulting in significant muscle glycogen sparing in
both type I and II muscle fibers after 3 h of exercise.
Carbohydrate ingestion inhibited adipose tissue lipolysis,
resulting in lower plasma FFA Ra, Rd, and Rox. The lower
total fat oxidation rate was entirely attributed to reduced
plasma FFA oxidation, as muscle IMTG use was not
affected by carbohydrate supplementation.
IMTG use during prolonged exercise
The importance of the IMTG pool as a substrate source
during exercise has been disputed. Many of the incon-
sistencies in the literature regarding IMTG use seem to be
explained by the methodological limitations associated
with the biochemical mixed-muscle TG extraction analyses
[46]. More recent studies using either stable isotope tracers,
1H-magnetic-resonance spectroscopy, electron microscopy,
and/or immunofluorescence microscopy on ORO stained
muscle cross-sections have now established that IMTG is
indeed a viable substrate source during exercise in healthy
humans [37]. In accordance, substantial net reductions in
type I muscle-fiber lipid content as assessed by immuno-
histochemical oil red O staining of muscle cross-sections
have been observed after both endurance and resistance
type exercise [11, 20, 41, 44]. Furthermore, our laboratory
has found a significant correlation between IMTG contents
assessed by biochemical TG extraction analyses and
immunofluorescence microscopy on ORO stained muscle
cross-sections (unpublished observations). In the present
study, we observed a significant 20±3 and 19±2%
contribution from muscle- and/or lipoprotein-derived TG
sources use during exercise in the CHO and CON trial,
respectively (Fig. 5). Concomitantly, muscle biopsy analy-
ses revealed a 76±21 and 78±22% net decline in type I
muscle-fiber IMTG content in the CHO and CON trial,
respectively (Fig. 6a). This translated in a 67±19 and 70±
20% decline in mixed-muscle intramycellular lipid content
in the CHO and CON trial, respectively.
Fig. 6 Fiber-type-specific net intramyocellular lipid and glycogen
utilization (expressed as mean arbitrary units ± SD, n=10) during 3 h
of cycling at 50% Wmax in CON and CHO trials. Asterisk, type II
significantly different than type I (P<0.05); Crosses, significantly
different from the CON trial (P<0.05)
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Earlier estimations [28] and more recent findings [41, 45]
show that the progressive increase in plasma FFA delivery
during the latter stages of prolonged exercise suppresses
IMTG mobilization and/or oxidation. In agreement, phar-
macological inhibition of adipose tissue lipolysis has been
shown to reduce plasma FFA availability and augments
IMTG use during exercise [42, 44, 47]. This possibly
suggests that during situations of decreased FFA availabil-
ity there is a compensatory increase in IMTG utilization in
vivo in humans. Carbohydrate supplementation during
exercise also inhibits adipose tissue lipolysis and reduces
plasma FFA availability [9, 10]. Therefore, it could be
speculated that carbohydrate supplementation could aug-
ment IMTG use during the latter stages of prolonged
exercise. In the present study, carbohydrate supplementa-
tion resulted in a 23±17% reduction in whole-body fat
oxidation because of the concerted reductions in adipose
tissue lipolysis with a concomitant 41±12% lower plasma
palmitate Ra, Rd, and Rox when compared with the CON
trial. Despite the attenuated increase in plasma FFA
availability in the CHO trial, no differences in estimated
IMTG use were observed between trials (Figs. 4b and 5). In
agreement, after exercise, type I muscle-fiber lipid content
was similarly reduced by 76±21 and 78±22% in the CHO
and CON trial, respectively (Fig. 6a).
In the present study, we did not observe any differences
in IMTG use after carbohydrate ingestion. This might be
because of the metabolic effects of increased glucose
availability in the CHO trial, as we observed a 49±9%
greater glucose Ra (Table 2) and a subsequent 48±9%
higher plasma glucose oxidation rate throughout exercise
(Fig. 4c). Furthermore, carbohydrate ingestion elevated
plasma insulin concentrations by nearly 60% in the first
hour of exercise vs CON (Fig. 2f). Elevated plasma insulin
is a potent inhibitor of adipose tissue lipolysis [6], resulting
in a substantially lower FFA availability in the CHO vs
CON trial (Table 2). Although reduced plasma FFA
availability could stimulate IMTG hydrolysis by reducing
the allosteric inhibition of hormone-sensitive lipase (HSL)
[44], we did not observe greater IMTG use in the CHO trial
(Figs. 4b and 6a). However, this elevated plasma insulin
could also serve to inhibit HSL activity, as a recent study
showed blunted HSL activity during exercise when glucose
is ingested [48]. Watt et al. [48] suggested that the
decreased HSLa was most likely mediated via increased
insulin and decreased epinephrine concentrations, and that
even in situations when local intramuscular mediators of
HSL are altered (i.e., muscle contraction, substrates/
products), the concurrent hormonal milieu may play a
greater role in the activation of HSL. This previous study
also found no effect of glucose ingestion on estimated
IMTG oxidation, despite a decrease in plasma FFA
availability and HSL activity [48].
Our present findings are not in line with de Bock et al.
[11], who reported attenuated IMTG use after carbohydrate
supplementation during a more intense exercise session in
less-well-trained subjects. As such, we conclude that the
proposed stimulating effects of reduced plasma FFA
availability on IMTG mobilization and/or oxidation are
offset by the inhibitory effects of carbohydrate supplemen-
tation on IMTG hydrolysis. The latter likely includes the
greater glycolytic flux (Table 2), concomitantly higher
circulating insulin (Fig. 2f), and decreased epinephrine
levels (Fig. 3), all of which have been associated with
reduced HSL activity in muscle tissue [48].
Effects of carbohydrate supplementation on muscle
glycogen use
It has been established that prolonged moderate-intensity
exercise results in greater glycogen depletion in type I vs
type II muscle fibers [8, 14]. In accordance, we observed a
73±25 and 42±18% greater net utilization of type I vs type
II muscle-fiber glycogen content in the CHO and CON
trial, respectively (Fig. 6b). This is the first study to show
glycogen sparing during prolonged cycling exercise in both
type I and II muscle fibers (Fig. 6b). This finding seems to
be in contrast to most previous studies that failed to
observed muscle glycogen sparing after carbohydrate
supplementation during cycling exercise [5, 9, 13, 17, 24,
25]. In line with our findings, some studies have also
reported muscle glycogen sparing after carbohydrate sup-
plementation during running exercise [34, 35]. However,
these studies reported muscle glycogen sparing to be
restricted to the type I muscle fibers only [34, 35]. The
apparent discrepancy with our findings is likely explained
by the differences in the type (running vs cycling) and
duration (1–2 vs 3 h) of the exercise that was implemented,
as with increasing exercise duration, muscle-fiber-type
recruitment shifts to include more type II fiber activation
as the type I fibers become glycogen depleted [15].
Our findings of muscle glycogen sparing with carbohy-
drate supplementation during prolonged constant intensity
cycling are in line with some [4, 12], but definitely not with
the majority of studies [5, 9, 13, 17, 24, 25]. The apparent
discrepancy between the current study and prior work that
failed to observe muscle glycogen sparing with carbohy-
drate supplementation during cycling might be explained
by differences in training status of the subjects, the intensity
and duration of the exercise, the amount and timing of the
ingested carbohydrate, the absence of the time-dependent
assessment of muscle glycogen use, and the lack of muscle-
fiber-type-specific glycogen analyses.
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In agreement with our findings of skeletal muscle
glycogen sparing, whole-body muscle glycogen use was
lower during the initial hour of exercise in the CHO vs
the CON trial (Fig. 5). In accordance to the hypothesis set
f o r t hb yC o g g a na n dC o y l e[ 7], we observed a greater
dependence on muscle glycogen as a substrate source
during the early stages of exercise in the CON trial
(Fig. 5). As exercise duration lengthened, the contribution
of muscle glycogen decreased over time as muscle
glycogen stores became depleted, while blood glucose
uptake and oxidation rates increased progressively
(Fig. 4). In line with this hypothesis, we observed lower
muscle glycogen use during the initial hour of exercise in
the CHO trial. At the onset of exercise, carbohydrate
administration caused a 49±9% greater plasma glucose Ra
and Rd in the CHO compared with the CON trial (Table 2),
which paralleled a 60% increase in plasma insulin
concentrations as compared to CON during the first hour
of exercise (Fig. 2). Concomitantly, these changes because
of the augmented glucose availability at exercise onset
decreased the reliance of muscle glycogen as a fuel source
during the first hour of exercise. The latter is in
accordance with a previous work reporting significant
glycogen sparing after carbohydrate supplementation after
60 min of running exercise [34]. We conclude that the
majority of glycogen sparing because of carbohydrate
supplementation occurs during the initial stages (<1 h) of
prolonged exercise, resulting in lowered glycogen utiliza-
tion in type I and II muscle fibers. As our findings show
that muscle glycogen sparing after carbohydrate supple-
mentation occurs early in exercise, endurance athletes
should be recommended to initiate sports-drink consump-
tion immediately at the onset of exercise to maximize the
potential for glycogen sparing, along with maintaining
euglycemia and high blood glucose oxidation rates late in
exercise.
Conclusions
This study provides compelling evidence that carbohydrate
supplementation spares muscle glycogen utilization in a
time-dependent manner during prolonged exercise in
endurance-trained cyclists. Carbohydrate supplementation
augments plasma glucose uptake and oxidation rate, while
reducing muscle glycogen use during the early stages of
exercise, thereby sparing type I and II muscle fiber
glycogen stores. Carbohydrate supplementation during
exercise lowers plasma FFA rate of appearance, uptake,
and oxidation, but does not modulate the use of IMTG as a
substrate source during cycling exercise.
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